Medtronic PLC vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Medtronic PLC trades at $87.75 (market cap $112.24B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.42 (market cap $962.24M). The key difference: Medtronic PLC is far larger — about 116.6× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Medtronic PLC pays a 3.28% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 56 Days on average.
| MDT | QDTE | |
|---|---|---|
Market Cap | $112.24B | $962.24M |
Volume | 105,663,236 | 882,859 |
Sector | Health | Income / Options Overlay |
52-Week High | $105.35 | $36.60 |
52-Week Low | $73.75 | $26.85 |
Typical Hold Time | 63 Days | 56 Days |
Enterprise Value | $131.58B | — |
Dividend Yield | 3.28% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
QDTE trades at $29.89, down 0.3% with a bullish technical signal despite overbought RSI readings. The ETF generates weekly income through covered call strategies but faces concerns about NAV erosion and return of capital. Recent distributions have declined from $0.28 to $0.11, reflecting shrinking yields as volatility decreases. The fund's 0.97% expense ratio consumes significant portions of payouts, creating structural challenges for long-term value preservation.
The outlook remains cautious as high distribution yields mask underlying NAV deterioration. While weekly income appeals to retail investors, the strategy underperforms in bull markets and faces sustainability questions. Key risks include volatility dependency, return of capital concerns, and competitive pressure from alternative income ETFs. Analyst sentiment is mixed with recent downgrades highlighting structural weaknesses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →